Literature DB >> 24349876

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.

Marie Vincent1, Agnès Quéméner1, Yannick Jacques1.   

Abstract

The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.

Entities:  

Keywords:  GD2 disialoganglioside; RLI superagonist; cancer therapy; immunocytokine; interleukin-15

Year:  2013        PMID： 24349876      PMCID： PMC3857326          DOI： 10.4161/onci.26441

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist.

Authors:  Erwan Mortier; Jérôme Bernard; Ariane Plet; Yannick Jacques
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

Review 2.  Immunocytokines: a novel class of potent armed antibodies.

Authors:  Nadine Pasche; Dario Neri
Journal:  Drug Discov Today       Date:  2012-01-24       Impact factor: 7.851

Review 3.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

4.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

5.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

Authors:  K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

Review 6.  Role of tumor-associated gangliosides in cancer progression.

Authors:  S Birklé; G Zeng; L Gao; R K Yu; J Aubry
Journal:  Biochimie       Date:  2003 Mar-Apr       Impact factor: 4.079

7.  Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Authors:  Marie Vincent; Anne Bessard; Denis Cochonneau; Géraldine Teppaz; Véronique Solé; Mike Maillasson; Stéphane Birklé; Laure Garrigue-Antar; Agnès Quéméner; Yannick Jacques
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

Review 8.  Twelve immunotherapy drugs that could cure cancers.

Authors:  Martin A Cheever
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors:  Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

10.  High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.

Authors:  Anne Bessard; Véronique Solé; Grégory Bouchaud; Agnès Quéméner; Yannick Jacques
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261
  10 in total
  9 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 2.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 3.  Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.

Authors:  Christian Fercher; Sahar Keshvari; Michael A McGuckin; Ross T Barnard
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-19

Review 4.  Trial Watch: Adoptive cell transfer for oncological indications.

Authors:  Fernando Aranda; Aitziber Buqué; Norma Bloy; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

Review 5.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

Review 6.  Cytokines in clinical cancer immunotherapy.

Authors:  Pedro Berraondo; Miguel F Sanmamed; María C Ochoa; Iñaki Etxeberria; Maria A Aznar; José Luis Pérez-Gracia; María E Rodríguez-Ruiz; Mariano Ponz-Sarvise; Eduardo Castañón; Ignacio Melero
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 7.  Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.

Authors:  Ombretta Melaiu; Valeria Lucarini; Loredana Cifaldi; Doriana Fruci
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

Review 8.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110

Review 9.  Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.

Authors:  Bassel Nazha; Cengiz Inal; Taofeek K Owonikoko
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.